About this pathway
Ecopipam is an antagonist of the dopamine D1 receptor (DRD1) in development for the treatment of Tourette Syndrome [Article:41693270]. It is primarily metabolized to ecopipam glucuronide by UGT1A9 [Articles:41693270, 41635062]. It can be converted by CYP3A4 to the minor but active metabolite n-desmethylecopipam, which can be also glucuronidated by UGT1A9 (metabolite not shown due to lack of chemical database cross reference) [Articles:41693270, 41635062].
Reactions & interactions (5)
-
Biochemical Reaction
ecopipam → n‐desmethylecopipam
-
Biochemical Reaction
ecopipam → ecopipam glucuronide
-
Catalysis
CYP3A4 → Biochemical Reaction
-
Catalysis
UGT1A9 → Biochemical Reaction
-
Inhibition
ecopipam → DRD1
Edit history (1)
- 2026-02-24 Create